natalizumab   Click here for help

GtoPdb Ligand ID: 6591

Synonyms: AN100226 | anti-alpha4 integrin | anti-VLA4 | Tysabri®
Approved drug Immunopharmacology Ligand
natalizumab is an approved drug (FDA (2004), EMA (2006))
Compound class: Antibody
Comment: Natalizumab was the first migration-inhibitory biological drug to be approved for inflammatory diseases. It targets α4β1 integrin (VLA-4) on leukocytes to block interaction with vascular cell adhesion molecule 1 (VCAM-1) on inflamed endothelium, thus inhibiting leukocyte extravasation into sites of inflammation. It is active in peripheral tissues and the central vervous system.
Targeting cell migration-related molecules in immune conditions (and cancer) is regarded as a valid approach for the development of novel anti-inflammatory therapeutics [3]. The design and synthesis of this antibody was originally described in a 1997 publication [2].

The first natalizumab biosimilar was approved by the FDA in August 2023. Like the originator/reference agent, Tyruko® (natalizumab-sztn; Sandoz Inc.) is indicated for relapsing forms of multiple sclerosis and moderate-severe active Crohn's disease (when conventional therapies, including TNF-α inhibitors, are inadequate or not tolerated).
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: natalizumab

Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2004), EMA (2006))
International Nonproprietary Names Click here for help
INN number INN
7716 natalizumab
Synonyms Click here for help
AN100226 | anti-alpha4 integrin | anti-VLA4 | Tysabri®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 75
Reactome Drug Reactome logo R-ALL-9679737
Reactome Reaction Reactome logo R-HSA-9679740
Other databases
GtoPdb PubChem SID 178103204
PubChem SID 178103204
Search PubMed clinical trials natalizumab
Search PubMed titles natalizumab
Search PubMed titles/abstracts natalizumab
Wikipedia Natalizumab